Features of TA-TMA include microangiopathic, Coombs-negative haemolytic anaemia and thrombocytopaenia, high serum lactate dehydrogenase (LDH) levels, decreased or undetectable haptoglobin levels, schistocytosis on peripheral blood smear, target organ damage and transfusion requirements. This evidence concerns the gene HP and Thrombocytopenia.